Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Insiders who purchased Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) shares in the past 12 months are unlikely to ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

Corvus Pharmaceuticals stock opened at $3.35 on Wednesday. The stock has a market cap of $215.26 million, a PE ratio of -3.60 and a beta of 0.91. The business’s 50-day moving average price is $4 ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Corvus Pharmaceuticals reported a wider-than-expected loss for the fourth quarter of 2024, with an earnings per share (EPS) of -$0.18, missing analyst forecasts of -$0.12. Following the announceme ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...